AzTrials
AzTrials

AnesthesiaNCT07352826

The Effect of Blood Carboxyhemoglobin Levels on NF-kB, NRF2 and PGC-1α During Low-flow and Normal-flow Anesthesia

A study testing low-flow anasthesia and Normal akımlı anestezi in people with Anesthesia, run by Ataturk Training and Research Hospital at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that exerts diverse biological effects across tissues and organs. At high concentrations, it is recognized as toxic because of harmful effects such as tissue hypoxia, oxidative stress, peroxynitrite formation, inflammation, apoptosis, and immune damage. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Anesthesia
What is being tested?
low-flow anasthesia and Normal akımlı anestezi
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteTurkey (Türkiye)
Study dates
20 Feb 2026to 31 Aug 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • aged 18-70 years
  • classified as ASA I
  • scheduled for inhalational anesthesia lasting ≥2 hours

Who cannot join

  • Patients with cardiovascular disease, respiratory system disease, hepatic or renal disease
  • pregnant or breastfeeding women
  • trauma patients
  • those undergoing emergency surgery
  • procedures lasting <2 hours
  • those receiving intraoperative blood transfusion
  • smokers
  • individuals who decline participation

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Veysel

    Erzurum

Other trials in Turkey (Türkiye)

About this study

Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that exerts diverse biological effects across tissues and organs. At high concentrations, it is recognized as toxic because of harmful effects such as tissue hypoxia, oxidative stress, peroxynitrite formation, inflammation, apoptosis, and immune damage. However, the endogenous production of CO suggests that it may confer protective mechanisms to the host. These protective effects include inhibition of platelet activation, smooth muscle relaxation, vasoactive properties, anti-inflammatory and anti-apoptotic actions, and beneficial influences on neurotransmission. Despite its toxic potential, low-concentration endogenous CO may provide protection linked to the body's defense mechanisms. In this study, we aimed to investigate the anti-apoptotic effects of carbon monoxide at low concentrations. To this end, the relationships between COHb levels and plasma levels of NF-κB, NRF2, and PGC-1α were analyzed statistically.

Read the detailed description

A total of 120 patients aged 18-70 years, classified as ASA I and scheduled for inhalational anesthesia lasting ≥2 hours, will be included. Patients with cardiovascular disease, respiratory system disease, hepatic or renal disease; pregnant or breastfeeding women; trauma patients; those undergoing emergency surgery; procedures lasting <2 hours; those receiving intraoperative blood transfusion; smokers; and individuals who decline participation will be excluded.

All participants who agree to join the study will read and sign an informed consent form describing the study. Preoperative evaluations will be performed 1 day before surgery. Thirty minutes before surgery, a 22G intravenous cannula will be inserted, and 8 mL of blood will be drawn into a yellow-cap gel biochemistry tube and 1.5 mL into a blood gas syringe containing 60 IU of dry heparin. Biochemistry samples will be centrifuged at 4000 rpm for 10 minutes in the medical biochemistry laboratory. The separated sera will be transferred to Eppendorf tubes and stored at -80 °C until the day of analysis. Blood gas samples will be analyzed on a blood gas analyzer (Radiometer ABL 520, Copenhagen, Denmark). After blood sampling, an infusion of 0.9% sodium chloride (NaCl) at 10 mL/kg/h will be initiated. Patients will receive IV premedication with 1.5 mg midazolam; on the operating table, ECG, noninvasive blood pressure, and peripheral oxygen saturation (SpO₂) will be monitored. Before induction, all patients will undergo preoxygenation with O₂ at 6 L/min via face mask for 3 minutes.

For induction of anesthesia, fentanyl 1 µg/kg (Fentanyl Citrate, Abbott Laboratories, North Chicago, USA) and propofol 2 mg/kg IV (Propofol, Fresenius Kabi, Sweden) will be administered over 20-30 seconds. After loss of the eyelash reflex, rocuronium bromide 0.6 mg/kg (Esmeron, Organon, Netherlands) will be given IV for neuromuscular blockade, and endotracheal intubation will be performed with a cuffed tube of appropriate size for the patient's age and body habitus. Following propofol administration and until intubation, all patients will be manually ventilated with 100% O₂. After intubation, mechanical ventilation will be provided with an anesthesia machine (Datex-Ohmeda Aisys CS2, Madison, USA) in volume-controlled mode with a tidal volume of 6-8 mL/kg, respiratory rate of 12-14/min, and PEEP of 5 cmH₂O. Soda lime will be used as the CO₂ absorbent (Sorbolime, Berkim, Türkiye), and replacement of the absorbent will be verified before induction for each patient.

Patients will be randomly assigned to one of two groups: Group LF (low-flow, n=60) and Group NF (normal-flow, n=60). In both groups, fresh gas flow (FGF) will be set at 4 L/min (O₂ 50%, air 50%) until the minimum alveolar concentration (MAC) reaches 1. In Group LF, FGF will then be maintained at 0.6 L/min (O₂ 50%, air 50%), with desflurane adjusted to maintain MAC = 1. In Group NF, FGF will be maintained at 2 L/min (O₂ 50%, air 50%), with desflurane adjusted to maintain MAC = 1. In both groups, blood sampling will be repeated at the 2nd hour of surgery.

During the final 30 minutes of surgery, patients will receive postoperative analgesia consisting of tramadol HCl (Contramal, Türkiye) 100 mg IV, paracetamol (Partemol, Türkiye) 1 g IV, and dexketoprofen (Ketavel, Türkiye) 50 mg IV. In the normal-flow group, after placement of the final skin suture, the inhalational agent will be discontinued and the carrier gas switched to 100% O₂; FGF will be increased to 8 L/min. In the low-flow group, the inhalational agent will be discontinued 20 minutes before the anticipated end of surgery; FGF will be maintained at 0.6 L/min until the final skin suture and then increased to 8 L/min. After the return of spontaneous breathing, neostigmine 0.03 mg/kg (Plantigmin, Türkiye) and atropine 0.01 mg/kg (Turktıpsan, Türkiye) will be administered in both groups to achieve extubation.

Postoperatively, patients will be transferred to the post-anesthesia care unit, where respiratory and hemodynamic parameters will be monitored for 30 minutes before transfer to the ward. In both groups, blood sampling will be repeated at postoperative hour 24 using the same method. The following variables will be recorded: duration of anesthesia, SpO₂, venous blood gas results, hemodynamic parameters, postoperative recovery time and quality, and postoperative complications (e.g., nausea and vomiting). Blood samples obtained in the preoperative, intraoperative, and postoperative periods will be centrifuged and stored at -80 °C. Following biochemical analysis, COHb, NF-κB, NRF2, and PGC-1α levels will be subjected to statistical analysis.

Conditions
Anesthesia
Being tested
low-flow anasthesia, Normal akımlı anestezi
Keywords
low flow anesthesia, COHb, NF-kB, NRF2, PGC-1 alpha

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • low-flow anasthesiaBehavioural

    In Group LF, FGF will then be maintained at 0.6 L/min (O₂ 50%, air 50%), with desflurane adjusted to maintain MAC = 1

  • Normal akımlı anesteziBehavioural

    In Group NF, FGF will be maintained at 2 L/min (O₂ 50%, air 50%) with desflurane adjusted to maintain MAC = 1..

Study groups in NCT07352826
Study groupRoleWhat they receive
low-flowExperimentallow flow
Receives: Behavioral: low-flow anasthesia; Behavioral: Normal akımlı anestezi
normal flowExperimentalnormal flow
Receives: Behavioral: low-flow anasthesia; Behavioral: Normal akımlı anestezi

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesia

    COHb concentrations

    Measured: 24 HOUR

  2. Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesia

    NF-kB concentrations

    Measured: 24 HOUR

  3. Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesi

    NRF2 concentrations

    Measured: 24 HOUR

  4. Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesi

    PGC-1α concentrations

    Measured: 24 HOUR

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jan 2026
  2. Study start20 Feb 2026
  3. Primary completion31 May 2026
  4. Study completion31 Aug 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
120 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07352826
Sponsor's protocol ID
B.30.2.YYU.0.01.00.00/91
Status last verified
Oct 2026
First submitted
15 Sep 2025
Last updated
21 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing low-flow anasthesia and Normal akımlı anestezi in people with Anesthesia, run by Ataturk Training and Research Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesia (time frame: 24 HOUR). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in